Baird Reiterates Outperform on Biogen, Maintains $340 Price Target
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Brian Skorney reiterates an Outperform rating on Biogen (NASDAQ:BIIB) and maintains a $340 price target.
June 07, 2023 | 5:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baird analyst Brian Skorney reiterates an Outperform rating on Biogen and maintains a $340 price target.
The reaffirmed Outperform rating and maintained price target by Baird analyst Brian Skorney indicates a positive outlook for Biogen's stock in the short term. This news is highly relevant and important for investors, as it suggests potential growth in the stock's value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100